Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Review Article Volume 4 Issue 4

Covid Associated Mucormycosis: What do we Know Till Now?

Vikasdeep Gupta1 and Vandana Sharma2*

1Department of Ophthalmology, All India Institute of Medical Sciences (AIIMS), Bathinda, India
2Department of Ophthalmology, Adesh Institute of Medical Sciences and Research (AIMSR), Bathinda, India

*Corresponding Author: Vandana Sharma, Department of Ophthalmology, Adesh Institute of Medical Sciences and Research (AIMSR), Bathinda, India.

Received: March 14, 2022; Published: March 28, 2022

Abstract

COVID 19 pandemic has overburdened the healthcare infrastructure in India in the last few months. As the second wave recedes, mucormycosis emerged as a new nemesis which is life and vision threatening to the already immunocompromised post COVID patients. This review article is written with the intent to identify a definitive approach towards early identification of the disease and to formulate guidelines for prompt management.

Keywords: Mucormycosis; COVID-19; Infrastructure

References

  1. Sharma S., et al. “Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum”. Journal of Laryngology and Otology 5 (2021): 442-447.
  2. Kontoyiannis DP., et al. “Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases”. Journal of Infectious Disease8 (2005): 1350-1360.
  3. V Saegeman., et al. “Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital”. Medical Mycology2 (2010): 245-254.
  4. Chayakulkeeree M., et al. “Zygomycosis: the re-emerging fungal infection”. European Journal of Clinical Microbiology and Infection Disease 4 (2006): 215-229.
  5. Kauffman CA. “Zygomycosis: reemergence of an old pathogen”. Clinical Infectious Diseases4 (2004): 588-590.
  6. Safdar A., et al. “Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis”. Bone Marrow Transplantation5 (2004): 467-468.
  7. Marr KA., et al. “Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients”. Clinical Infectious Diseases 7 (2002): 909-917.
  8. Roden MM., et al. “Epidemiology and outcome of zygomycosis: a review of 929 reported cases”. Clinical Infectious Diseases 5 (2005): 634-653.
  9. Chakrabarti A., et al. “Ten years' experience in zygomycosis at a tertiary care centre in India”. Journal of Infection4 (2001): 261-266.
  10. White L., et al. “A national strategy to diagnose coronavirus disease 2019 - associated invasive fungal disease in the intensive care unit”. Clinical Infectious Diseases (2020): ciaa1298.
  11. Gangneux JP., et al. “Invasive fungal diseases during COVID-19: we should be prepared”. Journal of Medical Mycology 30 (2020):
  12. Arnaiz-Garcý´a ME., et al. “Cutaneous mucormycosis: report of five cases and review of the literature”. Journal of Plastic, Reconstructive and Aesthetic Surgery 62 (2009): 434e441.
  13. Chamilos G., et al. “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis”. Clinical Infectious Diseases 47 (2008): 503-509.
  14. Liu J., et al. “Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV- 2 infected patients”. EBioMedicine 55 (2020):
  15. Waizel-Haiat S., et al. “A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19”. Cureus2 (2021): e13163.
  16. Sweeny JM., et al. “Evidence for secondary thrombotic microangiopathy in COVID-19”. MedRxiv preprint (2021).
  17. Vandroux D., et al. “Mortality of critically ill patients with severe influenza starting four years after the 2009 pandemic”. Infectious Disease11-12 (2019): 831-837.
  18. Scheckenbach K., et al. “Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis”. Auris Nasus Larynx 37 (2010): 322e328.
  19. Singh VP., et al. “Sinonasal Mucormycosis: A to Z”. Indian Journal of Otolaryngology and Head and Neck Surgery 71 (2019): 1962-1971.
  20. Shah K., et al. “Orbital Exenteration in Rhino-Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring System”. Indian Journal of Otolaryngology and Head and Neck Surgery2 (2019): 259-265.
  21. Mekonnen ZK., et al. “Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome”. Ophthalmic Plastic and Reconstructive Surgery2 (2021).
  22. E Bouza., et al. “Mucormycosis: an emerging disease?” Clinical Microbiology and Infection 12 (2006): 7-23.
  23. DeShazo RD., et al. “Fungal sinusitis”. The New England Journal of Medicine 337 (1997): 254-259.
  24. Millon L., et al. “Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)”. Clinical Microbiology and Infection22 (2016): 810.e1-810.e8.
  25. Lone PA., et al. “Rhino-orbito-cerebral mucormycosis: Magnetic resonance imaging”. Indian Journal of Otology 21 (2015): 215-218.
  26. Radner AB., et al. “Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: case report and review”. Clinical Infectious Diseases 20 (1995): 163-166.
  27. Piromchai P and Thanaviratananich S. “Impact of treatment time on the survival of patients suffering from invasive fungal rhinosinusitis”. Clinical Medicine Insights: Ear, Nose and Throat 7 (2014): 31-34.
  28. Walsh TJ., et al. “Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases”. Clinical Infectious Diseases 26 (1998): 1383-1396.
  29. Riley TT., et al. “Breaking the mold: a review of mucormycosis and current pharmacological treatment options”. Annals of Pharmacotherapy9 (2016): 747-757.
  30. Lewis RE., et al. “Activity of deferasirox in Mucorales: influences of species and exogenous iron”. Antimicrobial Agents and Chemotherapy 55 (2011): 411-413.
  31. Ibrahim AS., et al. “The iron chelator deferasirox protects mice from mucormycosis through iron starvation”. Journal of Clinical Investigation 117 (2007): 2649-2657. 

Citation

Citation: Vikasdeep Gupta and Vandana Sharma. “Covid Associated Mucormycosis: What do we Know Till Now?".Acta Scientific Otolaryngology 4.4 (2022): 70-74.

Copyright

Copyright: © 2022 Vikasdeep Gupta and Vandana Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In







News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US